IMC-P115C / Immunocore - LARVOL DELTA

Phase 1/2 clinical trials of brenetafusp and IMC-P115C (PRAME-A02 Half-Life Extended) in multiple solid tumors (Immunocore Press release) - "After observing an initial brenetafusp monotherapy signal in platinum-resistant ovarian cancer (PROC), the Company is evaluating, as part of an ongoing Phase 1/2 trial, combination therapy with bevacizumab in earlier lines, including platinum-sensitive ovarian cancer (PSOC). In the same trial, the Company continues signal detection across multiple metastatic non-small cell lung cancer (NSCLC) cohorts, including combinations with standards of care in earlier-line NSCLC. The Company is enrolling patients in the Phase 1 dose escalation trial evaluating IMC-P115C in patients with multiple solid tumors. The Company expects to present Phase 1/2 data from both trials in the second half of 2026."

First-in-human • P1/2 data • Platinum resistant • Platinum sensitive • Non Small Cell Lung Cancer • Ovarian Cancer • Solid Tumor

PRAME portfolio (GlobeNewswire) - "The Company is enrolling HLA-A*02:01 positive patients with first-line, advanced or metastatic cutaneous melanoma to brenetafusp 160 mcg + nivolumab or a control arm of either nivolumab or nivolumab + relatlimab...The Company continues to evaluate brenetafusp in a Phase 1/2 trial in combination in platinum-resistant ovarian cancer (PROC) and in earlier lines of platinum-sensitive ovarian cancer (PSOC). In the same trial, the Company continues signal detection in metastatic NSCLC cohorts, including combination in earlier-line NSCLC; The Company is enrolling patients in the Phase 1 dose escalation trial evaluating IMC-P115C in patients with multiple solid tumors; The Company expects to present Phase 1/2 data from both trials in the second half of 2026."

P1/2 data • Platinum resistant • Platinum sensitive • Trial status • Cutaneous Melanoma • Ovarian Cancer • Solid Tumor

PRAME programs (The Manila Times) - "Second half of 2026: Present data from Phase 1/2 brenetafusp combinations in ovarian, including platinum sensitive ovarian cancer; Second half of 2026: Present data from Phase 1/2 brenetafusp monotherapy and combinations in NSCLC; Second half of 2026: Present initial data from Phase 1 trial with IMC-P115C (PRAME-A02-HLE) in multiple solid tumors; Continue enrollment in Phase 3 brenetafusp combination trial in 1L cutaneous melanoma (PRISM-MEL-301)."

Clinical data • Platinum sensitive • Cutaneous Melanoma • Melanoma • Non Small Cell Lung Cancer • Ovarian Cancer • Solid Tumor

Study of IMC-P115C in Advanced PRAME-Positive Cancers (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Immunocore Ltd

New P1 trial • Oncology

Immunocore reports first quarter financial results and provides a business update (GlobeNewswire) - "Total net product revenue (or 'net sales') arising from the sales of KIMMTRAK (tebentafusp) was $93.9 million in the first quarter of 2025, an increase of 33% over the first quarter of 2024, of which $56.6 million was generated in the United States, $32.8 million in Europe and $4.5 million in international regions...The European Organisation for Research and Treatment of Cancer (EORTC) is enrolling patients in the Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM)....The Company is enrolling patients in the Phase 1 dose escalation trial, in multiple solid tumors, with IMC-P115C."

Enrollment status • Sales • Ocular Melanoma • Solid Tumor • Uveal Melanoma

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME (GlobeNewswire) - "Immunocore Holdings plc...announces that the first patient has been dosed in the Phase 1 trial of IMC-P115C (PRAME-HLE-A02), which is a half-life extended ImmTAC candidate....The Phase 1 dose escalation trial will evaluate the safety, pharmacokinetics and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with a range of advanced cancers expressing PRAME."

Trial status • Oncology • Solid Tumor

Immunocore reports second quarter financial results and provides a business update (GlobeNewswire) - "Phase 1/2 clinical trial of brenetafusp (PRAME-A02) in multiple solid tumors: The Company plans to present clinical data for brenetafusp in late-line non-small cell lung cancer (NSCLC) in the fourth quarter of 2024; IMC-T119C: Remain on track for regulatory submission of Investigational New Drug (IND) or Clinical Trial Application (CTA) for IMC-T119C in the fourth quarter of 2024; The CTA for IMC-R117C was accepted in April 2024 by the EMA, and the Phase 1 clinical trial is expected to start in the second half of 2024."

IND • New P1 trial • P1/2 data • Colorectal Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update (Immunocore Press release) - "IMC-P115C (PRAME HLA-A02 Half-Life Extended) & IMC-T119C (PRAME HLA-A24): The Company is expanding the PRAME franchise with two new PRAME ImmTAC candidates, IMC-P115C (PRAME HLA-A02 HLE) and IMC-T119C (PRAME HLA-A24) for solid tumors, which are both on track for investigational new drug (IND) or clinical trial application (CTA) submissions for IMC-P115C in the middle of 2024 and the fourth quarter of 2024 for IMC-T119C."

IND • Oncology • Solid Tumor

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation (GlobeNewswire) - "Advancing our PRAME franchise in multiple solid tumors and broadening the addressable population. Randomization is expected to begin in the first quarter of 2024 in the registrational trial for IMC-F106C in first-line advanced cutaneous melanoma (PRISM-MEL-301), and we expect to present data from the Phase 1/2 clinical trial monotherapy and combination cohorts throughout 2024. We further expect to submit investigational new drug (IND) applications or clinical trial applications (CTA) for IMC-P115C (PRAME HLA-A2 Half-Life-Extended) and IMC-T119C (PRAME HLA-A24) candidates in 2024."

IND • New trial • P1/2 data • Trial status • Cutaneous Melanoma • Gynecologic Cancers • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Skin Cancer • Solid Tumor

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) - "The Company continues to work on expanding the PRAME franchise, with pre-clinical work ongoing for two new PRAME ImmTAC candidates, IMC-P115C (PRAME-A02 HLE) and IMC-T119C (PRAME-A24) for solid tumors, with both on-track for investigational new drug (IND) or clinical trial application (CTA) submission in 2024; IMC-R117C (PIWIL1): The Company remains on-track to submit an IND/CTA in the fourth quarter of 2023 for IMC-R117C, an ImmTAC targeting the PIWIL1 protein for colorectal and other gastrointestinal cancers."

IND • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) - "The Company is on-track to submit an IND / CTA in the fourth quarter of 2023 for IMC-R117C, an ImmTAC targeting the PIWIL1 protein for colorectal and other gastrointestinal cancers. The Company believes this is the first PIWIL1-targeted immunotherapy in development. The Company continues to work on expanding the PRAME franchise, with pre-clinical work ongoing for two new PRAME ImmTAC candidates, IMC-P115C (PRAME-A02 HLE) and IMC-T119C (PRAME-A24) for solid tumors, with both on-track for IND/CTA submission in 2024."

IND • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Immunocore Reports 2022 Financial Results and Provides Business Update (GlobeNewswire) - "KIMMTRAK^® (tebentafusp-tebn) for metastatic uveal melanoma...The Company is undergoing reimbursement discussions in a number of countries, including Germany and France where the Company is currently receiving revenues. The Company expects reimbursement decisions in one additional major European country by mid-2023 and up to five smaller countries by end of 2023....Expansion of PRAME franchise: IMC-T119C (PRAME-A24) & IMC-P115C (PRAME-A02 HLE)....The Company plans to submit investigational new drug applications (INDs) for these two ImmTAC candidates in 2024."

IND • Reimbursement • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma